BioWorld

Nov. 22, 2002

Lundbeck Acquiring Synaptic, CNS Pipeline For $121M In Cash

Synaptic Pharmaceutical Corp. signed a definitive merger agreement with like-minded central nervous system-focused H. Lundbeck A/S in a deal worth about $121 million. (BioWorld Today) Read More

Jun Gene Encodes Enzyme That Links Obesity, Diabetes In Tissue Inflammation With Drug Designs

Inspire Starts Phase III Trial Of Drug For Allergic Rhinitis

Other News To Note

Inflazyme In Line For Up To $90M After Expanding Deal With Aventis

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

BioWorld

Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...

Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists

BioWorld Science

Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.